Rocket Pharmaceuticals officer proposes 2,216-share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Rocket Pharmaceuticals, Inc. (RCKT) reports that Gaurav Shah, an officer and director, filed notice of a proposed sale of 2,216 common shares, with an approximate market value of $4,827.56 and an approximate sale date of November 18, 2026. Shah acquired the shares from the issuer through restricted stock vesting on November 16, 2026, as compensation. The notice says the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
The notice also lists earlier sales by Shah: 2,293 common shares on August 18, 2026, for gross proceeds of $7,753.55, and 3,020 common shares on November 13, 2026, for gross proceeds of $6,795.91.
Key Figures
Key Terms
Restricted Stock Vesting financial
vested equity award distribution financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.